Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients with Breast Cancer

PHASE3TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 30, 2020

Primary Completion Date

September 30, 2024

Study Completion Date

January 30, 2025

Conditions

Breast Cancer

Interventions

DRUG

Goserelin acetate 3.6 mg Injection

3.6 mg, Subcutaneously at every 28 days

DRUG

ZOLADEX® 3.6mg Injection

3.6 mg, Subcutaneously at every 28 days

Trial Locations (1)

Mahatma Gandhi Cancer Hospital & Research Institute, Visakhapatnam